Navigation Links
Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
Date:11/8/2007

tein therapeutics used for the treatment of RA were greater than $9.5 billion.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP custom drug assembly technology. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information visit http://www.trubion.com.

Forward-Looking Statements

Certain statements in this release may constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933. These statements include, but are not limited to, those related to the company's future clinical development programs and the timing thereof, the company's expected financial and operating results, future clinical development plans, the details of the clinical trials and the results and timing thereof, and the timing of regulatory applications and action. These statements are based on current expectations and assumptions regarding future events and business performance and involve certain risks and uncertainties that could cause actual results to differ materially. These risks include, but are not limited to, risks associated with the company's Wyeth collaboration, including Wyeth's control over development timelines, the risk that the FDA may require modification
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
6. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
7. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
8. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
9. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
10. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
11. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... -- Atossa Genetics, Inc. (NASDAQ: ATOS ), The Breast ... , Chief Financial Officer & General Counsel, will present at ... 30, 2013, in New York City ... presentation is scheduled to begin at 3:30 p.m. EDT and ... webcast, go to www.atossagenetics.com . For more ...
(Date:5/17/2013)... 17, 2013  Boston Scientific Corporation (NYSE: ... EuroPCR Scientific Program May 21-24 in Paris ... a particularly rich and diversified set of data this ... , M.D., global chief medical officer, Boston Scientific.  "The ... including the NG PROMUS trial, which evaluated our Promus ...
(Date:5/16/2013)... 2013  Nektar Therapeutics, (Nasdaq: NKTR ) President ... , is scheduled to present at the upcoming 2013 UBS ... at the Sheraton New York Hotel on Tuesday, May 21, ... will be accessible via a Webcast through a link posted ... website: http://www.nektar.com . This Webcast will be available for ...
Breaking Medicine Technology:Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City 2
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG.OB) ... vertically integrated pharmaceutical company engaged in pharmaceutical related ... subsidiaries in the Anhui, Jilin, and Shandong provinces, ... first quarter ended March 31, 2011. ...
... Diagnostics, a leading developer of quantitative pulmonary imaging software, ... for the evaluation of pulmonary disease including chronic obstructive ... the 2011 International Conference of the American Thoracic Society ... been installed at leading pulmonary centers for validation and ...
Cached Medicine Technology:Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 2Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 3Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 4Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 5Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 6Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 7Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 8Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 9Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 10Global Pharm Holdings Group Announces First Quarter 2011 Financial Results 11VIDA Diagnostics Launches Apollo Pulmonary Analysis Software for Major Lung Disease at American Thoracic Society Meeting 2
(Date:5/18/2013)... 2013 As metal-on-metal hip implant ... country, Bernstein Liebhard LLP notes that a new study ... tissue damage before they experience any pain from a ... Daily will appear in the Journal of Bone & ... screens of their hips. The researchers found tissue ...
(Date:5/18/2013)... Although obesity is associated with an ... obesity and esophageal adenocarcinoma, a type of esophageal cancer, ... As reported on Cancer.gov, last reviewed in January ... likely as those of normal and healthy weight to ... and esophageal cancer is not well understood, it is ...
(Date:5/18/2013)... 2013 The “Sleep Apnea Diagnostic & ... Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] ... analyzes and studies the major market drivers, restraints, and ... the World. , Browse , ... Figures , 318 pagesand in-depth TOC ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 Adolescents, especially ... known as “Spice” or “K2” are landing in emergency ... to curb this drug epidemic with a new ... marijuana. , According to research from the National Institute ... popular illegal drug among American teenagers. In 2012, 11 ...
(Date:5/18/2013)... DF (PRWEB) May 18, 2013 The ... leading ayurvedic education institution in the West. Program is ... education. , Ayurveda is a healing modality practiced for ... ), it is considered that health begins when an ... profound understanding of their individual needs. Ayurveda aims to ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Spice Addiction Treatment and Synthetic Marijuana Drug Rehab Announced by Recovery Associates 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2
... 18 (HealthDay News) -- A new analysis of existing ... job of treating depression than standard care. Depression ... psychotherapy and antidepressant drugs. According to the analysis, one-third ... treated with four different medications. In addition, among depressed ...
... The BP oil spill in the Gulf of Mexico last ... coastal communities, even in areas where there was no direct ... of Maryland Medical Center and the University of Florida, Gainesville, ... in two fishing communities: Baldwin County, Ala., which had direct ...
... By Maryann Mott HealthDay Reporter , FRIDAY, Feb. ... best friends, but hospital records suggest some pooches feel otherwise. ... States are bitten by dogs, with some bites needing emergency ... hospital admissions caused by dog bites nearly doubled, increasing from ...
... the Children,s Center for Cancer and Blood Diseases and ... today announced a breakthrough discovery in understanding how the ... called CD19-ligand (CD19-L) located on the surface of certain ... of leukemia cells by the immune system. This ...
... , FRIDAY, Feb. 18 (HealthDay News) -- Tapping certain sequences ... German researchers suggest. For example, typing the numbers that ... trigger the feeling of that word in your mind, according ... University of Wurzburg. The researchers created a list of ...
... -- A disease the affects your legs could warn you ... million Americans over the age of 50 have peripheral arterial ... attack, according to the Vascular Disease Foundation and its PAD ... the foundation says. PAD occurs when arteries in the ...
Cached Medicine News:Health News:Peer Support Beats Usual Care for Depression, Analysis Finds 2Health News:Study Finds Widespread Trauma in Wake of BP Oil Spill 2Health News:Rise in Dog Bites Has Experts Concerned 2Health News:Rise in Dog Bites Has Experts Concerned 3Health News:Scientists bioengineer a protein to fight leukemia 2Health News:Using Cell Phones Might Evoke Emotions, Study Suggests 2Health News:Leg Discomfort Might Signal Heart Trouble 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: